Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study

• Published in: Journal of cancer research and clinical oncology Vol. 134; no. 9; pp. 1037 - 1042
• Main Authors: Vrzalikova, Katerina, Skarda, Joseph, Ehrmann, Jiri, Murray, Paul G., Fridman, Eduard, Kopolovic, Jury, Knizetova, Petra, Hajduch, Marian, Klein, Jiri, Kolek, Vitezslav, Radova, Lenka, Kolar, Zdenek
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.09.2008; Springer; Springer Nature B.V
• Subjects: Antineoplastic agents; Biological and medical sciences; Bmi protein; Cancer Research; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy; Female; Gene expression; Gene Expression Profiling; Hematology; Humans; Immunohistochemistry; Internal Medicine; Lung cancer; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Medical prognosis; Medical sciences; Medicine; Medicine & Public Health; Neoplasm Staging; Non-small cell lung carcinoma; Nuclear Proteins - genetics; Nuclear Proteins - metabolism; Oncology; Original Paper; Pharmacology. Drug treatments; Pneumology; Polycomb group proteins; Polycomb Repressive Complex 1; Prognosis; Protein Array Analysis; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; Repressor Proteins - genetics; Repressor Proteins - metabolism; Small cell lung carcinoma; Statistical analysis; Statistics; Tissue Array Analysis; Tumors; Tumors of the respiratory system and mediastinum; Tissue microarray; Bmi-1 oncogene; Non-small cell lung cancer; Polycomb genes; Human; Lung disease; Prognosis; PcG gene; Respiratory disease; Lung cancer; Malignant tumor; non-small cell lung carcinoma; Gene expression; BMI1 gene; Tissue microarrays; C-Onc gene; Oncoprotein; Bronchus disease; Genetics; Tissue microarray, Non-small cell lung cancer; Onc gene; Protooncogene; Bmi-1 oncogene·Polycomb genes; Cancer
• ISSN: 0171-5216; 1432-1335
• DOI: 10.1007/s00432-008-0361-y

Purpose Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes. Methods Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS. Results Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III ( P  = 10 −6 ) and stage IV ( P  = 10 −5 ) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts ( P  = 0.05). Conclusions Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.